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and older). The impact of arthritis on physical unhealthy days
was stronger among those aged 45–64. (Odds Ratio (OR) = 2.1
for aged 18–44; OR = 3.1 for aged 45–64; OR = 2.1 for aged
65 and older). Unlike a physical unhealthy day, younger people
were more likely to experience a mental unhealthy day in the
general adult population (42.0% for 18–44 years old; 33.4% for
45–64 years old; 17.8% for 65 and older). The impact of arthri-
tis on having mental “unhealthy day” was also stronger among
those aged 45–64 (OR = 1.8 for aged 18–44; OR = 2.3 for aged
45–64; OR = 1.3 for aged 65 and older). CONCLUSION: The
data shows that arthritis has a signiﬁcant impact on the experi-
ence of physical or mental unhealthy days. Although arthritis is
more prevalent among adults aged 65 and older, its impact on
mental “unhealthy days” was stronger among younger adults.
These ﬁndings should be considered in implementing public
health programs.
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OBJECTIVES: Colorectal cancer is the third most common
malignant neoplasm worldwide and the second leading cause of
cancer deaths in the United States. Advanced colorectal cancer
often presents as large bowel obstruction. With colonic stenting
the creation of a stoma can be avoided and procedural mortal-
ity can be reduced. The objective of this study is to compare the
outcomes and cost of colonic stenting compared to surgery for
large bowel obstruction. METHODS: We used the 2001
Medicare Standard Analytic Files to identify patients who under-
went colon stenting and surgery for large bowel obstruction
caused by colorectal cancer using a combination of procedure
codes and diagnosis codes. For each patient we analyzed the ﬁrst
stenting procedure (index event) we identiﬁed.. We summarized
patients’ demographic characteristics including age, sex and race.
Outcomes and resource utilization measures (inpatient and out-
patient costs, ER visits, in-hospital mortality, and length of stay)
were computed for the index hospitalization and 90-day follow-
up period. RESULTS: We identiﬁed 212 patients with stent
placements and 969 who underwent surgical intervention. The
two groups were similar in demographics and risk factors. In-
hospital mortality was lower for the stent group compared to the
surgery group but this difference was not statistically signiﬁcant
(8.0% versus 11.4%; p = 0.156). Emergency room visits during
the 90 day follow-up period was signiﬁcantly higher for the
surgery group (11.3% versus 17.0%; p = 0.040). Adjusted cost
for the 90-day follow-up period was $6726 (p = 0.000) lower
for the stent group compared to the surgery group. The 90-day
mortality was similar for the two groups CONCLUSION:
Patients who underwent stent placements appear to have fewer
complications during follow-up as they require fewer emergency
room visits. Stent placement appears to be less expensive than
surgery. Additional analysis with larger sample size and longer
follow-up is required to conﬁrm the results from this study.
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OBJECTIVES: Without accurate tumor localization, radiother-
apeutic efﬁcacy is suboptimal and sources of geometric varia-
tions, such as organ motion and patient movement, can result in
irradiation of normal tissues. An evidence-based health technol-
ogy assessment evaluated whether using a real-time 4D electro-
magnetic tumor tracking system, (Calypso® 4D Localization
System with Beacon® Transponders; “Calypso® 4D Localiza-
tion System;” Calypso Medical, Seattle, Washington), improves
the net health outcomes of patients irradiated for clinically local-
ized prostate cancer. METHODS: We addressed the following
questions: 1) Does the Calypso® 4D Localization System accu-
rately localize prostate tumors? 2) Does real-time 4D electro-
magnetic tracking reduce radiation-induced toxicity? 3) How do
the outcomes of real-time 4D electromagnetic tracking compare
to those of alternative technologies? Comparators included 
electronic portal imaging devices, computed tomography, 
ultrasound, and stereoscopic X-ray. We searched electronic 
bibliographic databases and systematically reviewed studies
reporting target shifts between treatment and linear accelerator
isocenters, percentages of shifts exceeding tolerable limits, radi-
ation-induced toxicities, and quality of life measurements.
Unpublished data on the Calypso® 4D Localization System were
also reviewed. RESULTS: Based on 1027 intra-subjects compar-
isons, the Calypso® 4D Localization System was statistically sig-
niﬁcantly (P < 0.0001) concordant with standard radiographic
localization. One prospective multicenter clinical trial showed
that the Calypso® 4D Localization System detected clinically
meaningful misalignments in 1174 of 1524 (77%) treatments for
41 patients positioned by conventional lasers and skin tattoos.
Complications from Beacon® Transponders placement were
comparable to those of transrectal biopsy and prostatic ﬁducial
implantation. Fifteen of 41 (35%) patients experienced minor
acute bladder toxicities; none experienced acute rectal compli-
cations. CONCLUSION: Published evidence suggests that real-
time 4D tracking confers greater accuracy than alternative
methods, but head-to-head clinical trials are lacking and there
are currently no alternative methods for real-time tumor track-
ing. This technology may also reduce overall treatment-related
morbidity; however, we await mature data on late toxicities and
tumor control.
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OBJECTIVES: The relationship between disease progression
endpoints and overall survival (OS) has been demonstrated in
colorectal, colon and non-small lung cancers (Johnson et al.
Lancet 2006; Sargent et al. JCO 2005). Patient access to novel
and efﬁcacious therapies for metastatic breast cancer (MBC)
could be expedited if disease progression was documented as a
valid surrogate outcome for OS in pivotal clinical trials. We
assessed the correlation between time to tumor progression
